Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
27 mars 2023 09h00 HE
|
Silo Pharma, Inc.
SPU-26 Pain Management Using Ketamine Composition Action supports planned IND package submission to FDA for SP-26 ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
15 mars 2023 08h40 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
13 févr. 2023 08h35 HE
|
Silo Pharma, Inc.
Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Announces Expansion of Intellectual Property Portfolio
02 févr. 2023 08h50 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces Stock Repurchase Program
31 janv. 2023 07h45 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
10 janv. 2023 10h15 HE
|
Silo Pharma, Inc.
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS,...
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
30 déc. 2022 08h10 HE
|
Silo Pharma, Inc.
SPU-21 effective in controlling arthritis progression. SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 ...
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
01 déc. 2022 09h00 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
21 nov. 2022 07h45 HE
|
Silo Pharma, Inc.
Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
11 nov. 2022 08h15 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...